|0.48|| 0.00 / 0.00%|
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.
|James E. Sapirstein||Chief Executive Officer & Director|
|John T. Cavan||Chief Financial Officer|
|John Z. Sullivan-Bólyai||Chief Medical Officer|
|Robert T. Foster||Chief Scientific Officer|
|Theresa Matkovits||Senior Vice President|